{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-22-002314","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2022-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.497530+00:00","generated_at":"2026-06-24T08:12:42.593960+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"vTv Therapeutics appoints Paul Sekhri as President and CEO effective August 1, 2022","bullets":["Paul Sekhri appointed President and CEO effective Aug 1, 2022; succeeds Richard Nelson, who becomes EVP and remains on board.","Employment terms: $480k base salary, 75% bonus target, 2.2M stock options at $0.79/share (NASDAQ inducement grant).","Options vest 25% after one year, then quarterly over three years; accelerated vesting on certain performance metrics.","Severance: 12 months base (18 months post-change of control), COBRA, target bonus; two-year non-compete and non-solicit.","vTv is preparing Phase 3 trials for TTP399 (type 1 diabetes) with recent $25M G42 investment and Breakthrough Therapy designation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-22-002314","json":"https://secwatch.observer/filing/0000950142-22-002314.json","markdown":"https://secwatch.observer/filing/0000950142-22-002314.md","text":"https://secwatch.observer/filing/0000950142-22-002314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/0000950142-22-002314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/eh220274048_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:12:42.593960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c05f1f68d","claim":"Richard S. Nelson changed role as Executive Vice President at vTv Therapeutics Inc..","evidence_excerpt":"As of the Effective Date, Richard S. Nelson will cease to be the Interim Chief Executive Officer but will continue to serve as a member of the Board and as an Executive Vice President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/0000950142-22-002314-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be Interim Chief Executive Officer"},{"label":"Role","value":"Executive Vice President"}],"fact_type":"executive_change"},{"claim_id":"c8f8f9150f","claim":"Paul Sekhri was appointed as President and Chief Executive Officer at vTv Therapeutics Inc..","evidence_excerpt":"On July 27, 2022, vTv Therapeutics Inc. (the “Company”) announced that the board of directors of the Company (the “Board”) has appointed Paul Sekhri as President and Chief Executive Officer and as a member of the Board, effective as of August 1, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/0000950142-22-002314-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}